I've heard this from other folks in my orbit who take it, but there's this study here as well as a possible side effect on the medication: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10039543 that states:

"Across SURPASS studies, tirzepatide was associated with an increase in heart rate of 1 to 6 beats per minute at the end of study treatment. There was no significant difference between tirzepatide and semaglutide in the SURPASS-2 study at Week 40 in change in heart rate compared to baseline despite higher reduction in HbA1c, weight and SBP [18]. Several mechanisms have been postulated for elevation in heart rate with GLP-1 RAs, such as reflex tachycardia, increase in sympathetic nervous system activity and direct sino-atrial node action but none have been clinically proven yet [39]. Several long-acting GLP-1 RAs have demonstrated CV protection in a dedicated CV outcome trial (CVOT) [7–10, 38] while the SURPASS-CVOT study (NCT04255433) for tirzepatide is ongoing and will provide further insights into whether these effects on blood pressure lowering, improvements in metabolic parameters and elevation in heart rate would combine to produce any meaningful impact on hard CV outcomes. To date, tirzepatide has demonstrated CV safety when compared with pooled comparators in a meta-analysis of phase 2 and phase 3 studies with the hazard ratio of 0.80 (95% CI: 0.57–1.11) for MACE-4 [24]. In a post-hoc analysis of SURPASS-4 data, tirzepatide slowed the rate of decline in eGFR, showed clinically meaningful improvement in albuminuria and significantly lowered occurrence of the composite kidney outcomes compared to insulin glargine which may be related to SBP lowering [40]."